|
FY2026
12 months to Jan 25, 2026
|
FY2025
12 months to Jan 26, 2025
|
FY2024
12 months to Jan 28, 2024
|
FY2023
12 months to Jan 29, 2023
|
FY2022
12 months to Jan 30, 2022
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Products | |||||
| Services | |||||
| Total net sales | |||||
| Cost of sales: | |||||
| Products | |||||
| Services | |||||
| Total cost of sales: | |||||
| Amortization of acquired technology | |||||
| Acquired technology impairments | |||||
| Total cost of sales | |||||
| Gross profit | |||||
| Operating expenses, net: | |||||
| Product development and engineering | |||||
| Selling, general and administrative | |||||
| Intangible amortization | |||||
| Restructuring | |||||
| Gain on sale of business | |||||
| Changes in the fair value of contingent earn-out obligations | |||||
| Intangible impairment | |||||
| Impairment of goodwill | |||||
| Total operating expenses, net | |||||
| Operating income (loss) | |||||
| Interest expense | |||||
| Interest income | |||||
| Loss on extinguishment of debt | |||||
| Non-operating (expense) income, net | |||||
| Investment impairments and credit loss reserves, net | |||||
| Loss before taxes and equity method income (loss) | |||||
| Provision (benefit) for income taxes | |||||
| Net loss before equity method income (loss) | |||||
| Equity method income (loss) | |||||
| Net loss | |||||
| Net income attributable to noncontrolling interest | |||||
| Net loss attributable to common stockholders | |||||
| Loss per share: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Weighted average number of shares used in computing loss per share: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...